SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Open Access
- 4 October 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (19)
Abstract
Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletinib (ENTO) is a second-generation highly selective SYK inhibitor with a high safety profile. Potential utility of ENTO as GVHD prophylaxis in patients was examined using a preclinical mouse model of eye and skin GVHD and ENTO-compounded chow. We found that early SYK inhibition improved blood immune cell reconstitution in GVHD mice and prolonged survival, with 60% of mice surviving to day +120 compared with 10% of mice treated with placebo. Compared with mice receiving placebo, mice receiving ENTO had dramatic improvements in clinical eye scores, alopecia scores, and skin scores. Infiltrating SYK + cells expressing B220 or F4/80, resembling SYK + cells found in lichenoid skin lesions of chronic GVHD patients, were abundant in the skin of placebo mice but were rare in ENTO-treated mice. Thus, ENTO given early after HCT safely prevented GVHD.Keywords
Funding Information
- National Institutes of Health (R01 HL 129061-01)
This publication has 69 references indexed in Scilit:
- Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliteransBlood, 2012
- Protective Role of T-bet and Th1 Cytokines in Pulmonary Graft-versus-Host Disease and Peribronchiolar FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something newBlood, 2011
- Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host diseaseBlood, 2011
- Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantationJournal of Clinical Investigation, 2010
- Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host diseaseBlood, 2009
- Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host diseaseBlood, 2009
- In vivo–activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host diseaseBlood, 2008
- High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host DiseaseClinical Cancer Research, 2007
- Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponseBlood, 2006